Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora.
Chemoprevention
Familial adenomatous polyposis
Intestinal flora
Metformin
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
25 Feb 2024
25 Feb 2024
Historique:
received:
01
09
2023
accepted:
03
02
2024
medline:
26
2
2024
pubmed:
26
2
2024
entrez:
25
2
2024
Statut:
epublish
Résumé
Metformin has been reported to inhibit the occurrence and development of colorectal cancer (CRC) by mediating changes in intestinal flora. Studies have also indicated that the occurence of familial adenomatous polyposis (FAP) may also be associated with changes in the intestinal flora. Therefore, we investigated the efficacy and safety of metformin in treating FAP and the association with intestinal flora. Compared with the baseline, the mean number and load of polyps in the areas of nanocarbon labeling and postoperative residuals in the test group were lower than those in the placebo group, while the diversity of intestinal flora species was increased. At the genus level, the relative abundance of g_Ruminococcus in the test group was lower than that at baseline, whereas the relative abundance of g_Lactobacillus was higher. These changes were statistically significant (P < 0.05). One-year metformin therapy for FAP is safe and effective, potentially mediated by modulating the intestinal flora. This study provides new insights and strategies for preventing adenomatous polyp carcinogenesis in FAP and explores possible preventive action.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Metformin has been reported to inhibit the occurrence and development of colorectal cancer (CRC) by mediating changes in intestinal flora. Studies have also indicated that the occurence of familial adenomatous polyposis (FAP) may also be associated with changes in the intestinal flora. Therefore, we investigated the efficacy and safety of metformin in treating FAP and the association with intestinal flora.
RESULTS
RESULTS
Compared with the baseline, the mean number and load of polyps in the areas of nanocarbon labeling and postoperative residuals in the test group were lower than those in the placebo group, while the diversity of intestinal flora species was increased. At the genus level, the relative abundance of g_Ruminococcus in the test group was lower than that at baseline, whereas the relative abundance of g_Lactobacillus was higher. These changes were statistically significant (P < 0.05).
CONCLUSION
CONCLUSIONS
One-year metformin therapy for FAP is safe and effective, potentially mediated by modulating the intestinal flora. This study provides new insights and strategies for preventing adenomatous polyp carcinogenesis in FAP and explores possible preventive action.
Identifiants
pubmed: 38403687
doi: 10.1186/s13023-024-03064-6
pii: 10.1186/s13023-024-03064-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Subventions
Organisme : the Foreign Cooperation Project of the Department of Science and Technology of Fujian Province
ID : 2022I0033
Organisme : Natural Science Foundation of Fujian Province
ID : 2023J011358
Organisme : intra-hospital issues at the 900th Hospital of the Joint Security Force
ID : 2020L07
Informations de copyright
© 2024. The Author(s).
Références
Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science. 1991;251(4999):1366–70.
pubmed: 1848370
Liang S, Mao Y, Liao M, Xu Y, Chen Y, Huang X, Wei C, Wu C, Wang Q, Pan X, Tang W. Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps. Int J Biol Sci. 2020;16:135–46.
pubmed: 31892851
pmcid: 6930378
Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018;359:592–7.
pubmed: 29420293
pmcid: 5881113
Attard TM, Septer S, Lawson CE, Attard MI, Lee STM, Umar S. Microbiome insights into pediatric familial adenomatous polyposis. Orphanet J Rare Dis. 2022;17(1):416.
pubmed: 36376984
pmcid: 9664625
Monahan KJ, Bradshaw N, Dolwani S, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69(3):411–44.
pubmed: 31780574
Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946–52.
pubmed: 10874062
Burke CA, Phillips R, Berger MF, et al. Children’s international polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol. 2017;10:177–85.
pubmed: 28765715
pmcid: 5525455
Burn J, Bishop DT, Chapman PD, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4(5):655–65.
pubmed: 21543343
Giardiello FM, Hamilton SR, Hylind LM, et al. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res. 1997;57(2):199–201.
pubmed: 9000553
Meyskens FL, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008;1(1):32–8.
pubmed: 18841250
Rad E, Murray JT, Tee AR. Oncogenic signalling through mechanistic target of rapamycin (mTOR): a driver ofmetabolic transformation and cancer progression. Cancers (Basel). 2018;10(1):5.
pubmed: 29301334
Faller WJ, Jackson TJ, Knight JR, et al. mTORC1-mediated translational elongation limits intestinal tumourinitiation and growth. Nature. 2015;517(7535):497–500.
pubmed: 25383520
Yuksekkaya H, Yucel A, Gumus M, et al. Familial adenomatous polyposis; succesful use of sirolimus. AmJ Gastroenterol. 2016;111(7):1040–1.
Cruz-Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4(8):1035–8.
pubmed: 16757216
Ishikawa H, Wakabayashi K, Suzuki S, et al. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2(1):50–6.
pubmed: 24133627
pmcid: 3797560
Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–80.
pubmed: 15713944
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–102.
pubmed: 15713943
Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010;3(9):1077–83.
pubmed: 20810669
Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17(4):475–83.
pubmed: 26947328
Dazhou LI. Chemopreventive effect of metformin on colorectal cancer. Naval Medical University; 2016. (in Chinese).
Gui-lin XU, Dazhou LI, Zhou YE, et al. The effect of metformin combined with endoscopy in the treatment of familial adenomatous polyposis. Chin J Clin Gastroenterol. 2020;32(02):84–9 (in Chinese).
Dazhou LI, Wen WANG, Binbin XU, et al. Chemopreventive mechanism of metformin or celecoxib on chemically induced colorectal aberrant crypt foci in mice. J Fujian Med Univ. 2016;50(03):163–6 (in Chinese).
Zhang X, Zhao Y, Xu J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 2015;5:14405.
pubmed: 26396057
pmcid: 4585776
De la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017;40(1):54–62.
pubmed: 27999002
Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850–8.
pubmed: 28530702
Fujimori T, Kato K, Fujihara S, et al. Antitumor effect of metformin on cholangiocarcinoma: in vitro and in vivo studies. Oncol Rep. 2015;34(6):2987–96.
pubmed: 26398221
Gagnaire A, Nadel B, Raoult D, Neefjes J, Gorvel JP. Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. Nat Rev Microbiol. 2017;15(2):109–28.
pubmed: 28045107
Huang X, Hong X, Wang J, et al. Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis. EBioMedicine. 2020;61: 103037.
pubmed: 33039709
pmcid: 7553239
Fan L, Zeng X, Xu G. Metformin regulates gut microbiota abundance to suppress M2 skewing of macrophages and colorectal tumorigenesis in mice. J Microbiol. 2023;61(1):109–20.
pubmed: 36701104
Kim JH, Kim YJ, Oh GM, Jung W, Park SJ. How is gut microbiome of patients with familial adenomatous polyposis different from healthy people? Medicine (Baltimore). 2022;101(49): e32194.
pubmed: 36626451
Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 2012;11(3):549–60.
pubmed: 22222629
Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008;99(11):2136–41.
pubmed: 18803638
Park JJ, Kim BC, Hong SP, et al. The effect of metformin in treatment of adenomas in patients with familial adenomatous polyposis. Cancer Prev Res (Phila). 2021;14(5):563–72.
pubmed: 33509804
Yuzhao LIU, Yingshan SUN, Yangang WANG, et al. Effects of metformin on serum homocysteine level and intestinal flora in diabetes rats. Shandong Med J. 2023;63(07):50–4 (in Chinese).
Fengyi Y, Zhun S, Fangming Y, et al. Impacts of Metformin treatment on the gut microbiota in newly⁃diagnosed type 2 diabetes mellitus patients. Chin J Diabetes. 2022;30(09):672–7 (in Chinese).
Liu Z, Liao W, Zhang Z, et al. Metformin affects gut microbiota composition and diversity associated with amelioration of dextran sulfate sodium-induced colitis in mice. Front Pharmacol. 2021;12: 640347.
pubmed: 34122067
pmcid: 8191634
Ternes D, Tsenkova M, Pozdeev VI, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression. Nat Metab. 2022;4(4):458–75.
pubmed: 35437333
pmcid: 9046088
Liu NN, Jiao N, Tan JC, et al. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nat Microbiol. 2022;7(2):238–50.
pubmed: 35087227
pmcid: 8813618
Qu X, Yin F, Pei M, et al. Modulation of intratumoral fusobacterium nucleatum to enhance sonodynamic therapy for colorectal cancer with reduced phototoxic skin injury. ACS Nano. 2023;17(12):11466–80.
pubmed: 37201179
pmcid: 10311605
Duggan WP, Salvucci M, Kisakol B, et al. Increased Fusobacterium tumoural abundance affects immunogenicity in mucinous colorectal cancer and may be associated with improved clinical outcome. J Mol Med (Berl). 2023;101(7):829–41.
pubmed: 37171483
Grahnemo L, Nethander M, Coward E, et al. Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome [published correction appears in Lancet Diabetes Endocrinol. 2022 Sep;10(9):e9]. Lancet Diabetes Endocrinol. 2022;10(7):481–483.
Burke CA, Dekker E, Lynch P, et al. Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis. N Engl J Med. 2020;383(11):1028–39.
pubmed: 32905675